{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:41:21Z","timestamp":1792460481762,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["22010901121"],"award-info":[{"award-number":["22010901121"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.lfs.2023.122186","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:42:46Z","timestamp":1697542966000},"page":"122186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Targeting neuromuscular junction to treat neuromuscular disorders"],"prefix":"10.1016","volume":"333","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-7172","authenticated-orcid":false,"given":"Rizwan","family":"Qaisar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2023.122186_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.610964","article-title":"The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis","volume":"13","author":"Rodriguez Cruz","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0010","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1167\/iovs.06-0073","article-title":"Identification of acetylcholine receptor subunits differentially expressed in singly and multiply innervated fibers of extraocular muscles","volume":"47","author":"Fraterman","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.lfs.2023.122186_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1196\/annals.1405.016","article-title":"The role of glial cells in the formation and maintenance of the neuromuscular junction","volume":"1132","author":"Feng","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2023.122186_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cophys.2018.05.007","article-title":"NMJ maintenance and repair in aging","volume":"4","author":"Taetzsch","year":"2018","journal-title":"Curr. Opin. Physiol."},{"issue":"10","key":"10.1016\/j.lfs.2023.122186_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102183","article-title":"The structure of human neuromuscular junctions: some unanswered molecular questions","volume":"18","author":"Slater","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0030","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.celrep.2017.11.008","article-title":"Cellular and molecular anatomy of the human neuromuscular junction","volume":"21","author":"Jones","year":"2017","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.lfs.2023.122186_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13225","article-title":"Neuron-specific deletion of CuZnSOD leads to an advanced sarcopenic phenotype in older mice","volume":"19","author":"Bhaskaran","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.lfs.2023.122186_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-physiol-022516-034255","article-title":"Neuromuscular junction formation, aging, and disorders","volume":"80","author":"Li","year":"2018","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.lfs.2023.122186_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101966","article-title":"Neuromuscular junction transmission failure in aging and sarcopenia: the nexus of the neurological and muscular systems","volume":"89","author":"Arnold","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0050","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1152\/physrev.00033.2014","article-title":"Mechanisms regulating neuromuscular junction development and function and causes of muscle wasting","volume":"95","author":"Tintignac","year":"2015","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.lfs.2023.122186_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046663","article-title":"Agrin and synaptic laminin are required to maintain adult neuromuscular junctions","volume":"7","author":"Samuel","year":"2012","journal-title":"PLoS One"},{"issue":"7 Pt 1","key":"10.1016\/j.lfs.2023.122186_bb0060","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1523\/JNEUROSCI.15-07-04796.1995","article-title":"Neurotrophins promote maturation of developing neuromuscular synapses","volume":"15","author":"Wang","year":"1995","journal-title":"J. Neurosci."},{"issue":"50","key":"10.1016\/j.lfs.2023.122186_bb0065","doi-asserted-by":"crossref","first-page":"11719","DOI":"10.1523\/JNEUROSCI.4087-05.2005","article-title":"Distinct mechanisms for neurotrophin-3-induced acute and long-term synaptic potentiation","volume":"25","author":"Je","year":"2005","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0070","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1083\/jcb.200603061","article-title":"Neurotrophin 3 induces structural and functional modification of synapses through distinct molecular mechanisms","volume":"175","author":"Je","year":"2006","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0075","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/mt.2013.250","article-title":"AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy","volume":"22","author":"Sahenk","year":"2014","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0080","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14737175.2021.1935242","article-title":"Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies","volume":"21","author":"Pisciotta","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"3\u20134","key":"10.1016\/j.lfs.2023.122186_bb0085","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41434-021-00231-3","article-title":"AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1","volume":"29","author":"Ozes","year":"2022","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0090","doi-asserted-by":"crossref","first-page":"fcab252","DOI":"10.1093\/braincomms\/fcab252","article-title":"AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in Gars(P278KY\/+) mice","volume":"3","author":"Ozes","year":"2021","journal-title":"Brain Commun."},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0095","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1096\/fj.13-240390","article-title":"Neuron-specific expression of CuZnSOD prevents the loss of muscle mass and function that occurs in homozygous CuZnSOD-knockout mice","volume":"28","author":"Sakellariou","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2023.122186_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114278","article-title":"Delayed viral vector mediated delivery of neurotrophin-3 improves skilled hindlimb function and stability after thoracic contusion","volume":"360","author":"Sydney-Smith","year":"2023","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.lfs.2023.122186_bb0105","first-page":"1306","article-title":"AAV1.NT-3 gene therapy prevents age-related sarcopenia","volume":"15","author":"Ozes","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"10.1016\/j.lfs.2023.122186_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13303","article-title":"AAV1.NT-3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia","volume":"14","author":"Tong","year":"2023","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41434-018-0009-8","article-title":"AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model","volume":"25","author":"Yalvac","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2023.122186_bb0120","doi-asserted-by":"crossref","first-page":"9345970","DOI":"10.1155\/2016\/9345970","article-title":"Characteristics of skeletal muscle fibers of SOD1 knockout mice","volume":"2016","author":"Nagahisa","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.lfs.2023.122186_bb0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.freeradbiomed.2016.03.025","article-title":"Muscle fiber type diversification during exercise and regeneration","volume":"98","author":"Qaisar","year":"2016","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"10.1016\/j.lfs.2023.122186_bb0130","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0135","first-page":"CD003279","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2011","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1060028019864574","article-title":"Amifampridine for the management of Lambert-Eaton Myasthenic syndrome: a new take on an old drug","volume":"54","author":"Yoon","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"10.1016\/j.lfs.2023.122186_bb0145","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1007\/s00415-022-11231-7","article-title":"Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial","volume":"269","author":"Bonanno","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.lfs.2023.122186_bb0150","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.lfs.2023.122186_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Med."},{"issue":"1\u20132","key":"10.1016\/j.lfs.2023.122186_bb0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2012.02.010","article-title":"3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis","volume":"245","author":"Mori","year":"2012","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0165","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.90.4.1624","article-title":"ARIA, a protein that stimulates acetylcholine receptor synthesis, also induces tyrosine phosphorylation of a 185-kDa muscle transmembrane protein","volume":"90","author":"Corfas","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0170","article-title":"Neuregulin in health and disease","volume":"4","author":"Cespedes","year":"2018","journal-title":"Int. J. Brain Disord. Treat."},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0175","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1523\/JNEUROSCI.15-09-06124.1995","article-title":"ARIA is concentrated in nerve terminals at neuromuscular junctions and at other synapses","volume":"15","author":"Sandrock","year":"1995","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0180","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1083\/jcb.201107083","article-title":"Neuregulin\/ErbB regulate neuromuscular junction development by phosphorylation of alpha-dystrobrevin","volume":"195","author":"Schmidt","year":"2011","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13395-018-0175-9","article-title":"The effects of neuregulin-1beta on intrafusal muscle fiber formation in neuromuscular coculture of dorsal root ganglion explants and skeletal muscle cells","volume":"8","author":"Qiao","year":"2018","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.lfs.2023.122186_bb0190","article-title":"Neuregulin-1, a potential therapeutic target for cardiac repair","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0195","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.3664","article-title":"Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-tooth disease 1A","volume":"20","author":"Fledrich","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2023.122186_bb0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clinph.2022.02.020","article-title":"The landscape of neurophysiological outcome measures in ALS interventional trials: a systematic review","volume":"137","author":"Ahmed","year":"2022","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.lfs.2023.122186_bb0205","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fnins.2014.00252","article-title":"ALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease","volume":"8","author":"Moloney","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.lfs.2023.122186_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693309","article-title":"Gene therapy overexpressing neuregulin 1 type I in combination with neuregulin 1 type III promotes functional improvement in the SOD1(G93A) ALS mice","volume":"12","author":"Modol-Caballero","year":"2021","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","article-title":"LRP4 serves as a coreceptor of agrin","volume":"60","author":"Zhang","year":"2008","journal-title":"Neuron"},{"issue":"24","key":"10.1016\/j.lfs.2023.122186_bb0220","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1242\/dev.02696","article-title":"LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction","volume":"133","author":"Weatherbee","year":"2006","journal-title":"Development"},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0225","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/gtc.12370","article-title":"Postnatal knockdown of dok-7 gene expression in mice causes structural defects in neuromuscular synapses and myasthenic pathology","volume":"21","author":"Eguchi","year":"2016","journal-title":"Genes Cells"},{"issue":"45","key":"10.1016\/j.lfs.2023.122186_bb0230","doi-asserted-by":"crossref","first-page":"11468","DOI":"10.1523\/JNEUROSCI.2508-08.2008","article-title":"Identification of a motif in the acetylcholine receptor beta subunit whose phosphorylation regulates rapsyn association and postsynaptic receptor localization","volume":"28","author":"Borges","year":"2008","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neuron.2007.06.031","article-title":"Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction","volume":"55","author":"Chen","year":"2007","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0896-6273(00)80751-5","article-title":"Alternatively spliced isoforms of nerve- and muscle-derived agrin: their roles at the neuromuscular junction","volume":"23","author":"Burgess","year":"1999","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0245","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0896-6273(01)00287-2","article-title":"Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation","volume":"30","author":"Yang","year":"2001","journal-title":"Neuron"},{"issue":"Pt 22","key":"10.1016\/j.lfs.2023.122186_bb0250","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1242\/jcs.072090","article-title":"Specific proteolytic cleavage of agrin regulates maturation of the neuromuscular junction","volume":"123","author":"Bolliger","year":"2010","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0255","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1083\/jcb.153.7.1441","article-title":"Effects of purified recombinant neural and muscle agrin on skeletal muscle fibers in vivo","volume":"153","author":"Bezakova","year":"2001","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0260","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1073\/pnas.94.6.2654","article-title":"Induction by agrin of ectopic and functional postsynaptic-like membrane in innervated muscle","volume":"94","author":"Jones","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.lfs.2023.122186_bb0265","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1523\/JNEUROSCI.17-17-06534.1997","article-title":"Neural agrin induces ectopic postsynaptic specializations in innervated muscle fibers","volume":"17","author":"Meier","year":"1997","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0270","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jcsm.13189","article-title":"C-terminal agrin fragment as a biomarker of muscle wasting and weakness: a narrative review","volume":"14","author":"Monti","year":"2023","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.lfs.2023.122186_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2022.104721","article-title":"A multistrain probiotic improves handgrip strength and functional capacity in patients with COPD: a randomized controlled trial","volume":"102","author":"Karim","year":"2022","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.lfs.2023.122186_bb0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neures.2022.08.004","article-title":"Elevated plasma zonulin and CAF22 are correlated with sarcopenia and functional dependency at various stages of Alzheimer\u2019s diseases","volume":"184","author":"Karim","year":"2022","journal-title":"Neurosci. Res."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0285","doi-asserted-by":"crossref","first-page":"8632","DOI":"10.1038\/s41598-021-87974-6","article-title":"Prediction of sarcopenia using a battery of circulating biomarkers","volume":"11","author":"Qaisar","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0290","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s12031-022-01970-7","article-title":"Evaluation of sarcopenia using biomarkers of the neuromuscular junction in Parkinson\u2019s disease","volume":"72","author":"Karim","year":"2022","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088739","article-title":"Injection of a soluble fragment of neural agrin (NT-1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction","volume":"9","author":"Hettwer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2023.122186_bb0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fncel.2018.00017","article-title":"Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy","volume":"12","author":"Boido","year":"2018","journal-title":"Front. Cell. Neurosci."},{"issue":"5","key":"10.1016\/j.lfs.2023.122186_bb0305","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/mus.26025","article-title":"Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis","volume":"57","author":"Li","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lfs.2023.122186_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.594220","article-title":"Modulation of the acetylcholine receptor clustering pathway improves neuromuscular junction structure and muscle strength in a mouse model of congenital myasthenic syndrome","volume":"13","author":"Spendiff","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043730","article-title":"Clinical and pathologic features of congenital myasthenic syndromes caused by 35 genes-a comprehensive review","volume":"24","author":"Ohno","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0320","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41598-017-18307-9","article-title":"Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment","volume":"8","author":"Petrov","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0325","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lfs.2023.122186_bb0335","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front. Neurol."},{"issue":"20","key":"10.1016\/j.lfs.2023.122186_bb0340","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1212\/WNL.0b013e3182749eca","article-title":"Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3","volume":"79","author":"Wadman","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0345","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1212\/WNL.0000000000011230","article-title":"Correlates of fatigability in patients with spinal muscular atrophy","volume":"96","author":"Bartels","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.lfs.2023.122186_bb0350","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clinph.2023.06.024","article-title":"Enhanced low-threshold motor unit capacity during endurance tasks in patients with spinal muscular atrophy using pyridostigmine","volume":"154","author":"Habets","year":"2023","journal-title":"Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0355","doi-asserted-by":"crossref","first-page":"fcac324","DOI":"10.1093\/braincomms\/fcac324","article-title":"Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4","volume":"5","author":"Stam","year":"2023","journal-title":"Brain Commun."},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0360","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019932","article-title":"Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)","volume":"8","author":"Stam","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0365","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/HJH.0000000000002932","article-title":"Pyridostigmine ameliorates preeclamptic features in pregnant rats by inhibiting tumour necrosis factor-alpha synthetsis and antagonizing tumour necrosis factor-alpha-related effects","volume":"39","author":"Issotina Zibrila","year":"2021","journal-title":"J. Hypertens."},{"key":"10.1016\/j.lfs.2023.122186_bb0370","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijcard.2016.10.061","article-title":"Impact of exercise training associated to pyridostigmine treatment on autonomic function and inflammatory profile after myocardial infarction in rats","volume":"227","author":"Feriani","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2023.122186_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135155","article-title":"Collagens at the vertebrate neuromuscular junction, from structure to pathologies","volume":"735","author":"Legay","year":"2020","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0380","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00401-018-1860-9","article-title":"Collagen VI is required for the structural and functional integrity of the neuromuscular junction","volume":"136","author":"Cescon","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065095","article-title":"Collagen VI in the musculoskeletal system","volume":"24","author":"Di Martino","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.lfs.2023.122186_bb0390","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1080\/15548627.2016.1231279","article-title":"Autophagy activation in COL6 myopathic patients by a low-protein-diet pilot trial","volume":"12","author":"Castagnaro","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.lfs.2023.122186_bb0395","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/139194","article-title":"Cyclosporine A in Ullrich congenital muscular dystrophy: long-term results","volume":"2011","author":"Merlini","year":"2011","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0400","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/ar.24092","article-title":"Collagen XIII and other ECM components in the assembly and disease of the neuromuscular junction","volume":"303","author":"Heikkinen","year":"2020","journal-title":"Anat. Rec. (Hoboken)"},{"issue":"11","key":"10.1016\/j.lfs.2023.122186_bb0405","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/hmg\/ddx101","article-title":"Collagen XIII secures pre- and postsynaptic integrity of the neuromuscular synapse","volume":"26","author":"Haronen","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"25","key":"10.1016\/j.lfs.2023.122186_bb0410","doi-asserted-by":"crossref","first-page":"23092","DOI":"10.1074\/jbc.M107583200","article-title":"The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin","volume":"277","author":"Tu","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0415","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ajhg.2015.10.017","article-title":"Congenital myasthenic syndrome type 19 is caused by mutations in COL13A1, encoding the atypical non-fibrillar collagen type XIII alpha1 chain","volume":"97","author":"Logan","year":"2015","journal-title":"Am. J. Hum. Genet."},{"issue":"17","key":"10.1016\/j.lfs.2023.122186_bb0420","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1523\/JNEUROSCI.3119-17.2018","article-title":"Collagen XIII is required for neuromuscular synapse regeneration and functional recovery after peripheral nerve injury","volume":"38","author":"Zainul","year":"2018","journal-title":"J. Neurosci."},{"issue":"37","key":"10.1016\/j.lfs.2023.122186_bb0425","doi-asserted-by":"crossref","first-page":"12230","DOI":"10.1523\/JNEUROSCI.5518-09.2010","article-title":"Muscle-derived collagen XIII regulates maturation of the skeletal neuromuscular junction","volume":"30","author":"Latvanlehto","year":"2010","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0430","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00424-020-02376-3","article-title":"Skeletal muscle ClC-1 chloride channels in health and diseases","volume":"472","author":"Altamura","year":"2020","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.lfs.2023.122186_bb0435","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fncel.2015.00156","article-title":"ClC-1 chloride channels: state-of-the-art research and future challenges","volume":"9","author":"Imbrici","year":"2015","journal-title":"Front. Cell. Neurosci."},{"issue":"18","key":"10.1016\/j.lfs.2023.122186_bb0440","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1113\/JP270358","article-title":"ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation","volume":"593","author":"Imbrici","year":"2015","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0445","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbadis.2014.05.019","article-title":"Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms","volume":"1852","author":"Meola","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0450","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1038\/s41598-019-39676-3","article-title":"Elucidating the contribution of skeletal muscle ion channels to amyotrophic lateral sclerosis in search of new therapeutic options","volume":"9","author":"Camerino","year":"2019","journal-title":"Sci. Rep."},{"issue":"Pt 3","key":"10.1016\/j.lfs.2023.122186_bb0455","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1113\/jphysiol.2007.141358","article-title":"Disuse of rat muscle in vivo reduces protein kinase C activity controlling the sarcolemma chloride conductance","volume":"584","author":"Pierno","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.lfs.2023.122186_bb0460","series-title":"Treasure Island (FL) Ineligible Companies. Disclosure: Mahdi Alsaleem declares no relevant financial relationships with ineligible companies","author":"Bryan","year":"2023"},{"issue":"Pt 1","key":"10.1016\/j.lfs.2023.122186_bb0465","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/awp294","article-title":"The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment","volume":"133","author":"Matthews","year":"2010","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11357-013-9544-9","article-title":"An olive oil-derived antioxidant mixture ameliorates the age-related decline of skeletal muscle function","volume":"36","author":"Pierno","year":"2014","journal-title":"Age (Dordr.)"},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0475","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjp.0702107","article-title":"Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channels","volume":"125","author":"De Luca","year":"1998","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0480","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13690","article-title":"Chloride channel inhibition improves neuromuscular function under conditions mimicking neuromuscular disorders","volume":"233","author":"Pedersen","year":"2021","journal-title":"Acta Physiol. (Oxford)"},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0485","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-3565(24)37710-9","article-title":"Chronic administration of taurine to aged rats improves the electrical and contractile properties of skeletal muscle fibers","volume":"286","author":"Pierno","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6203","key":"10.1016\/j.lfs.2023.122186_bb0490","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1126\/science.1250744","article-title":"Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction","volume":"345","author":"Arimura","year":"2014","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.lfs.2023.122186_bb0495","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jb\/mvs013","article-title":"Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment","volume":"151","author":"Yamanashi","year":"2012","journal-title":"J. Biochem."},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0500","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1074\/jbc.M708607200","article-title":"Mutations causing DOK7 congenital myasthenia ablate functional motifs in Dok-7","volume":"283","author":"Hamuro","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"7867","key":"10.1016\/j.lfs.2023.122186_bb0505","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-021-03672-3","article-title":"Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia","volume":"595","author":"Oury","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0510","doi-asserted-by":"crossref","first-page":"880","DOI":"10.15252\/emmm.201607298","article-title":"DOK7 gene therapy enhances motor activity and life span in ALS model mice","volume":"9","author":"Miyoshi","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0515","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2020.07.031","article-title":"AAV9-DOK7 gene therapy reduces disease severity in Smn(2B\/\u2212) SMA model mice","volume":"530","author":"Kaifer","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.lfs.2023.122186_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101385","article-title":"DOK7 gene therapy enhances neuromuscular junction innervation and motor function in aged mice","volume":"23","author":"Ueta","year":"2020","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.lfs.2023.122186_bb0525","doi-asserted-by":"crossref","first-page":"47","DOI":"10.32607\/actanaturae.11063","article-title":"Muscle-specific promoters for gene therapy","volume":"13","author":"Skopenkova","year":"2021","journal-title":"Acta Nat."},{"issue":"6832","key":"10.1016\/j.lfs.2023.122186_bb0530","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/35074025","article-title":"Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse","volume":"410","author":"Lin","year":"2001","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.lfs.2023.122186_bb0535","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1523\/JNEUROSCI.19-09-03376.1999","article-title":"Constitutively active MuSK is clustered in the absence of agrin and induces ectopic postsynaptic-like membranes in skeletal muscle fibers","volume":"19","author":"Jones","year":"1999","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0540","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1083\/jcb.200105034","article-title":"MuSK induces in vivo acetylcholine receptor clusters in a ligand-independent manner","volume":"155","author":"Sander","year":"2001","journal-title":"J. Cell Biol."},{"issue":"41","key":"10.1016\/j.lfs.2023.122186_bb0545","doi-asserted-by":"crossref","first-page":"8860","DOI":"10.1523\/JNEUROSCI.0860-18.2018","article-title":"Sarcoglycan alpha mitigates neuromuscular junction decline in aged mice by stabilizing LRP4","volume":"38","author":"Zhao","year":"2018","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.lfs.2023.122186_bb0550","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.celrep.2014.07.061","article-title":"Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging","volume":"8","author":"Carnio","year":"2014","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.lfs.2023.122186_bb0555","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nbt0897-768","article-title":"Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv","volume":"15","author":"Xie","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122186_bb0560","first-page":"7","article-title":"Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody","author":"Cantor","year":"2018","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0565","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.celrep.2012.08.004","article-title":"Increasing MuSK activity delays denervation and improves motor function in ALS mice","volume":"2","author":"Perez-Garcia","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.lfs.2023.122186_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101305","article-title":"The emerging role of the sympathetic nervous system in skeletal muscle motor innervation and sarcopenia","volume":"67","author":"Delbono","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.122186_bb0575","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1073\/pnas.1524272113","article-title":"Sympathetic innervation controls homeostasis of neuromuscular junctions in health and disease","volume":"113","author":"Khan","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2023.122186_bb0580","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mcn.2019.01.007","article-title":"Sympathomimetics regulate neuromuscular junction transmission through TRPV1, P\/Q- and N-type Ca(2+) channels","volume":"95","author":"Rodrigues","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"issue":"6","key":"10.1016\/j.lfs.2023.122186_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061677","article-title":"The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes","volume":"19","author":"Rodriguez Cruz","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2023.122186_bb0590","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.nmd.2012.11.004","article-title":"Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations","volume":"23","author":"Burke","year":"2013","journal-title":"Neuromuscul. Disord."},{"issue":"10","key":"10.1016\/j.lfs.2023.122186_bb0595","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/jnnp-2012-304716","article-title":"Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1","volume":"84","author":"Finlayson","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.lfs.2023.122186_bb0600","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mus.22176","article-title":"Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia","volume":"44","author":"Liewluck","year":"2011","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.lfs.2023.122186_bb0605","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1212\/WNL.0000000000001952","article-title":"Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes","volume":"85","author":"Rodriguez Cruz","year":"2015","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.lfs.2023.122186_bb0610","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","article-title":"Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II","volume":"29","author":"Frongia","year":"2019","journal-title":"Neuromuscul. Disord."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523008214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523008214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T17:41:44Z","timestamp":1752860504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320523008214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":122,"alternative-id":["S0024320523008214"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122186","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting neuromuscular junction to treat neuromuscular disorders","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122186"}}